Objective: To assess the efficacy of cerebrolysin in patients with cranial/brain injury of moderate severity. Material and methods: The main group included 30 patients treated with cerebrolysin from the first day of disease, the comparison group included 32 patients matched for age, sex and disease severity. Results and Conclusion: Cerebrolysin promoted the early and complete reduction of common symptoms of brain injury as well as autonomic and asthenic disorders, restoration of cognitive functions, normalization of emotional condition, improvement of spontaneous bioelectrical activity. The drug was well-tolerated.